Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?
Geburtshilfe und Frauenheilkunde · 01.03.2023 · 83 (03) · 321-332
DOI: 10.1055/a-1921-9336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.03.2023. Verfasst von Natalia Krawczyk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Frauenheilkunde und Geburtshilfe der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Introduction
HER2 positivity is one of the most important predictive factors in the treatment of breast cancer patients. Thanks to new targeted anti-HER2 drugs, the prognosis for HER2-positive breast cancer patients has been significantly improved, and the treatment can now be designed according to the risk situation and the response to treatment. At the same time, these innovative targeted anti-HER2 drugs are associated with high costs and require long and involved patient care. Materials and Methods In this paper, we compare the treatment costs of three post-neoadjuvant treatment regimens (trastuzumab vs. trastuzumab/pertuzumab vs. T-DM1) in early stage HER2-positive breast cancer from the perspective of the oncological outpatient clinic of a certified breast center at a university hospital, and evaluate the cost coverage.
Results
The highest costs in systemic therapy were the material costs. These were the highest for dual blockade with trastuzumab/pertuzumab, followed by T-DM1 and trastuzumab monotherapy. According to our study, all three of these post-neoadjuvant therapy variants achieve a positive contribution margin. While all three models have similar contribution margins, the treatment pathway with T-DM1 is associated with a 30% lower contribution margin.
Conclusions
Although these model calculations are associated with limitations in view of the introduction of biosimilar antibodies, it can be shown that modern therapeutic approaches do not always have to be associated with lower profits.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Klinik für Frauenheilkunde und Geburtshilfe der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
- Kooperatives Brustzentrum Paderborn, Frauen- und Kinderklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Paderborn, Germany.
- Institut für Workflow-Management im Gesundheitswesen (IWiG), c/o Europäische Fachhochschule - University of Applied Sciences - Hochschule für Gesundheit, Soziales und Pädagogik, Rheine, Germany.
Förderung
- Pfizer
Zitieren
APA
Krawczyk, N., Ruckhäberle, E., Lux, M. P., Fehm, T., Greiling, M., & Osygus, M. (2023). Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?. Geburtshilfe und Frauenheilkunde, 83(03), 321-332. https://doi.org/10.1055/a-1921-9336
Vancouver
Krawczyk N, Ruckhäberle E, Lux MP, Fehm T, Greiling M, Osygus M. Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?. Geburtshilfe und Frauenheilkunde. 2023;83(03):321-332. doi:10.1055/a-1921-9336
BibTeX
@article{Krawczyk2023,
author = {Krawczyk, Natalia and Ruckhäberle, Eugen and Lux, Michael Patrick and Fehm, Tanja and Greiling, Michael and Osygus, Michael},
title = {Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?},
journal = {Geburtshilfe und Frauenheilkunde},
year = {2023},
volume = {83},
number = {03},
pages = {321--332},
doi = {10.1055/a-1921-9336}
}
EUVIMED